No

Name of the deliverable

Lead Beneficiary

SOP - Strategy - Guidance document

D5.01

Report on identification and setting of categorization, read-across, and extra/interpolation criteria

12

 

D5.02

Report on the development of a solubility testing procedure

12

 

D5.03

In vitro screening methodology for absorption or crossing of other barriers

22

SOPs available in deliverable:

  • SOP 01 Protocol for organotypic cell culture modified for exposure to nanomaterials
  • SOP 02 Caco-2 cell culture and differentiation
  • SOP 03 Evaluation of NMs impact on Caco-2 cell barrier model

D5.04

In vitro screening methodology to evaluate toxicity by inhalation

11

 

D5.05

Report on cell type and in vitro-in vivo correlation studies for inhalation toxicity

43

 

D5.06

Identification and optimization of the most suitable in vitro methodology

 

SOPs available in deliverable:

  • SOP 01 LAL Assay for Nanoparticles
  • SOP 02 LDH assay
  • SOP 03 Reaction Oxygen Species Detection
  • SOP 04 Human Lung Cell transformation assay. Long term chronic experiment
  • SOP 05 Apoptosis/Necrosis Analysis
  • SOP 06 Production of pro-inflammatory cytokines

D5.07

Develop a rapid high throughput screening methodology to evaluate NM toxicity

39

 
      SOP 01 SOP for Dispersion
      SOP 02 Real-time label-free impedance-based nanotoxicity assessment
      SOP 03 SOP for High Throughput Cell Impedance Measurement
      SOP 04 Label-free nanotoxicity assessment by impedance-based flow cytometry
      SOP 05 Viability protocol by using a Cell Counter
      SOP 06 HEL16T008 AlamarBlue Assay
      SOP 07 HEL17T010 Colony forming efficiency assay
      SOP 08 Cytotoxicity by MTS - reference to NanoValid protocol
      SOP 09 TaqMan real-time Reverse Transcription PCR
      SOP 10 HEL11T005 HTS Comet Assay with and without FPG - 12 wells
      SOP 11 HTS Comet Assay with and without FPG - 20 wells
      SOP 12 HEL11T007 Mammalian in vitro HPRT Mutation test
      SOP 13 HEL16T009 Mouse Lymphoma Assay in vitro
      SOP 14 Micronucleus Assay
      SOP 15 Micronucleus assay using Flow Cytometry
      SOP 16 High Content Analysis-based nanotoxicity assessment
      SOP 17 Ion Beam Microscopy
      SOP 18 Confocal Raman Mcrospectroscopy
      SOP 19 Whole blood cell assay for cytokine production

D5.08

Decision tree for risk assessment of MNMs

5

RIVM FlowChart NANoREG nanospecific risk assessment strategy
D5.09 Summary report WP5    

If not indicated otherwise, the information in the NANoREG Results Repository is available under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Information on “commercial use” and attribution can be found here.